CABIO Biotech Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 508

Employees

  • Stock Symbol
  • 688089

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.51
  • (As of Tuesday Closing)

CABIO Biotech General Information

Description

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Contact Information

Website
www.cabio.cn
Formerly Known As
Cabio Bioengineering (Wuhan) Co. Ltd., CABIO-Bioengineering, Cabio Bioengineering Co. Ltd, Cabio Bioengineering, Kerry Symbio Bioengineering, Cabio Bioengineering (Wuhan)
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • No. 999, Gaoxin Avenue, East Lake New Technology Development Zone
  • Wuhan, Hubei 430073
  • China
+86 027
Primary Industry
Food Products
Other Industries
Biotechnology
Stock Exchange
SHG
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • No. 999, Gaoxin Avenue, East Lake New Technology Development Zone
  • Wuhan, Hubei 430073
  • China
+86 027

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CABIO Biotech Stock Performance

As of 14-Jan-2025, CABIO Biotech’s stock price is $2.51. Its current market cap is $423M with 168M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.51 $2.40 $1.40 - $4.16 $423M 168M 4.66M $0.09

CABIO Biotech Financials Summary

As of 30-Sep-2024, CABIO Biotech has a trailing 12-month revenue of $70.5M.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 457,123 389,171 706,610 1,049,070
Revenue 70,509 62,729 64,358 54,376
EBITDA 17,786 20,757 14,860 26,233
Net Income 16,000 12,915 9,558 19,913
Total Assets 237,382 227,336 233,551 227,246
Total Debt 2,607 1,801 4,790 379
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CABIO Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CABIO Biotech‘s full profile, request access.

Request a free trial

CABIO Biotech Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

CABIO Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019299299-A1 Method for lowering iodine value of glyceride Active 04-Jul-2018
AU-2019299299-B2 Method for lowering iodine value of glyceride Active 04-Jul-2018

CABIO Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CABIO Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CABIO Biotech‘s full profile, request access.

Request a free trial

CABIO Biotech Investments & Acquisitions (4)

CABIO Biotech’s most recent deal was a Merger/Acquisition with Oebiotech. The deal was made on 28-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Oebiotech 28-Oct-2024 Merger/Acquisition Diagnostic Equipment
JUSHU 13-Jan-2023 Early Stage VC Biotechnology
PuDuZhongHe 08-Jan-2023 Early Stage VC Diagnostic Equipment
MIT Technology Review China 29-Jun-2022 Later Stage VC Publishing
To view CABIO Biotech’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

CABIO Biotech FAQs

  • When was CABIO Biotech founded?

    CABIO Biotech was founded in 1999.

  • Where is CABIO Biotech headquartered?

    CABIO Biotech is headquartered in Wuhan, China.

  • What is the size of CABIO Biotech?

    CABIO Biotech has 508 total employees.

  • What industry is CABIO Biotech in?

    CABIO Biotech’s primary industry is Food Products.

  • Is CABIO Biotech a private or public company?

    CABIO Biotech is a Public company.

  • What is CABIO Biotech’s stock symbol?

    The ticker symbol for CABIO Biotech is 688089.

  • What is the current stock price of CABIO Biotech?

    As of 14-Jan-2025 the stock price of CABIO Biotech is $2.51.

  • What is the current market cap of CABIO Biotech?

    The current market capitalization of CABIO Biotech is $423M.

  • What is CABIO Biotech’s current revenue?

    The trailing twelve month revenue for CABIO Biotech is $70.5M.

  • What is CABIO Biotech’s annual earnings per share (EPS)?

    CABIO Biotech’s EPS for 12 months was $0.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »